Boyd Watterson & Amber Infrastructure Jointly Announce Strategic Transaction
30.5.2024 15:00:00 EEST | Business Wire | Press release
Boyd Watterson Asset Management, LLC (“Boyd Watterson”) (www.boydwatterson.com) and Amber Infrastructure Group Holdings Limited (“Amber”) (www.amberinfrastructure.com) jointly announced that the businesses will come together under a common parent company to create a global diversified Real Estate, Infrastructure, and Fixed Income asset management platform (the “Company”). Upon closing, the Company through its operating subsidiaries will be a premier global alternatives investment manager with over three-hundred investment personnel, offices in eight US cities and twelve countries. The firm will have approximately $35.7 billion in assets under management. While the financial terms of the transaction have not been disclosed, the Company’s shareholders upon closing will be comprised of the existing shareholders in Boyd Watterson and Amber.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240530809315/en/
Founded in 1928 by its predecessor firm, Boyd Watterson is headquartered in Cleveland, OH and has $18.2 billion in total assets under management (“AUM”) across its Real Estate and Fixed Income investment portfolios. Boyd has a reputation for creating bespoke investment solutions that deliver attractive, risk-adjusted returns to its clients.
Founded in 2009, Amber is headquartered in London, UK and oversees £14 billion or approximately US$17.5 billion in AUM. Amber specializes in mobilizing private capital to deliver essential infrastructure projects globally across sectors.
Hunt Companies (www.huntcompanies.com), an investor in both companies, recognized the complementary businesses and facilitated the transaction.
“With the combination of Amber Infrastructure Group, we are broadening our scope and opening up exciting new investment opportunities for our clients,” said Brian Gevry, CEO of Boyd Watterson. “We are both recognized leaders in our asset classes with exceptional talent who continually strive to outperform customer expectations. Now we will have greater reach and ability to build on each team’s respective expertise to deliver products and performance to a global client base.”
Brian Gevry will serve as Chairman and CEO of the combined parent entity, and Gavin Tait, Amber’s current CEO, will continue to serve as the head of Amber and oversee the Infrastructure business globally, reporting to Brian Gevry.
“We are very excited about integrating with Boyd Watterson and the long-term investment outlook this alignment brings to our customers,” said Tait. “Both firms have a keen focus on delivering outstanding client service and proven expertise in partnering with governments around the world. The planned combination will create greater scale for Amber to grow its global infrastructure business, including US Infrastructure opportunities, while bringing new opportunities for Boyd Watterson’s clients.”
The transaction is subject to Boyd Watterson’s and Amber’s respective client and investor consent processes as well as UK FCA consent and other customary regulatory approvals.
Transaction Rationale
Boyd Watterson’s and Amber’s clients, partners, and employees should benefit significantly from the enhanced scale of the combined, global platform underpinned by a diversified revenue base, expanded product opportunities, and enhanced investment acumen. In summary, the transaction:
- Provides a robust business model for both companies by enhancing the size and scale of both organizations to the benefit of their respective clients.
- Creates broader scope with a diversified investment platform enhancing Boyd Watterson’s and Amber’s shared heritage as long-term, trusted partners to clients, government entities, tenants, employees, and investors.
- Combines two teams with demonstrated track record and deep expertise in their respective, government-linked sectors.
- Combines culturally aligned partners with like-minded management.
- Expands global reach and provides new investment opportunities and access to capital.
- Provides opportunities to strategically enhance systems and share business best practices.
Advisors
For Boyd Watterson, Berkshire Global Advisors served as financial advisor and Goodwin Procter LLP served as legal advisor. Dechert LLP served as legal advisor to Amber and Hunt. Milbank LLP served as legal advisor to Amber’s minority shareholders.
About Boyd Watterson
Founded in 1928 by its predecessor firm, Boyd Watterson Asset Management, LLC (Boyd) is a leading real estate and fixed income investment manager. Headquartered in Cleveland, Ohio, Boyd employs 130 employees in seven offices across the US. Boyd manages c.US$18.2bn of AUM, through separately managed accounts and a number of funds with real estate and fixed income strategies. www.boydwatterson.com
About Amber Infrastructure Group
Amber is a specialist international investment manager, focused on investment origination, asset management and fund management. Amber currently manages or advises 9 funds (2 listed and 7 private) with over £5billion (c.$6billion) in funds under management. With a presence across 12 countries, Amber manages 175 infrastructure investments representing total assets under management of £14 billion (c.$17.5billion). Amber’s core business focuses on managing infrastructure assets across the public, transport, energy, digital and demographic infrastructure sectors internationally. Amber is headquartered in London with offices in Europe, North America, Australia and New Zealand. Amber employs over 180 professionals globally. www.amberinfrastructure.com
About Hunt Companies
Hunt Companies is a family-owned principal investment firm founded in 1947 based in El Paso, TX with interests in the real estate, infrastructure and financial services sectors. As an owner operator with a strong investment platform and financial structuring expertise, Hunt develops lasting relationships to create value for its investors, clients, employees and communities. The company and its affiliates are committed to promoting community growth and a sustainable future through our business practices, purpose driven investment and charitable giving. www.huntcompanies.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240530809315/en/
Contact information
Carolyn Baker
SVP Corporate Communications
Hunt Companies
carolyn.baker@huntcompanies.com
m: +1 856/298-2036
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
